Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force
Cindy Strehl, Frank Buttgereit(Humboldt-Universität zu Berlin), Maurizio Cutolo(Ospedale Policlinico San Martino), Simon Tarp(Frederiksberg Hospital), Annette de Thurah(Aarhus University Hospital), David Ray(Manchester Royal Infirmary), Joachim Listing(German Rheumatism Research Centre), N. Caeyers(National Patient Safety Foundation), Maarten Boers(Amsterdam UMC Location Vrije Universiteit Amsterdam), Maarten de Wit(Cal Humanities), Xavier Mariette(Inserm), T. Huizinga(Leiden University Medical Center), Dieter Wiek(Deutsche Rheuma-Liga), Bhaskar Dasgupta(Southend University Hospital NHS Foundation Trust), J. W. J. Bijlsma, Raphaèle Séror(Université Paris-Sud), Rinie Geenen(University of Udine), William G Dixon(University of Manchester), Alison Kent(Salisbury NHS Foundation Trust), Kevin Winthrop(Oregon Health & Science University), Cornelia M Spies(Charité - Universitätsmedizin Berlin), Hans Ulrich Scherer(Leiden University)
Cited by 331
Related Papers
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
|Arthritis Care & Research|2012|1.8k
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis
|Annals of the Rheumatic Diseases|2013|1.4k
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci
|Nature Genetics|2010|1.3k
Effect of Collagen Turnover on the Accumulation of Advanced Glycation End Products
|Journal of Biological Chemistry|2000|957